Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia

References

• Lalami Y, Paesmans M, Aoun M, et al. A prospective randomized evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia. Support Care Canc 2004;12:725-7-30
   PubMed Web of Science ®Google Scholar
• Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427-37
   PubMed Web of Science ®Google Scholar
• Kuderer N, Dale D, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor or febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-67
   PubMed Web of Science ®Google Scholar
• Paessens B, von Schilling C, Berger K, et al. Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients. Ann Oncol 2011;22:2310-19
   PubMed Web of Science ®Google Scholar
• Weycker D, Barron R, Kartashov A, et al. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract 2014;20:190-8
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 2013;24:2475-84
   PubMed Web of Science ®Google Scholar
• Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 2011;77:221-40
   PubMed Web of Science ®Google Scholar
• Calhoun E, Chang CH, Welshman E, et al. The impact of chemotherapy delays on quality of life in patients with cancer. J Support Oncol 2004;2;64-5
   Google Scholar
• Wingard JR, Elmongy M. Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibiotics. Crit Rev Oncol Hematol 2009;72:144-54
   PubMed Web of Science ®Google Scholar
• Raposo CG, Marin AP, Barón MG. Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia. Clin Translat Oncol 2006;8:729-34
   PubMedGoogle Scholar
• NEUPOGEN® (filgrastim) Prescribing Information. Amgen, Thousand Oaks, CA; June 2016. http://pi.amgen.com/∼/media/amgen/repositorysites/pi-amgen-com/neupogen/neupogen_pi_hcp_english.ashx. [Last accessed 11 July 2017]
   Google Scholar
• NEULASTA® (pegfilgrastim) Prescribing Information. Amgen, Thousand Oaks, CA; December 2016. http://pi.amgen.com/∼/media/amgen/repositorysites/pi-amgen-com/neulasta/neulasta_pi_hcp_english.ashx. [Last accessed 11 July 2017]
   Google Scholar
• Aapro MS, Bohlius J, Cameron DA. et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neu- tropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8-32
   PubMed Web of Science ®Google Scholar
• National Comprehensive Center Network. 2016 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Myeloid growth factors version 2.2016. 2016;1–47. https://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf. [Last accessed 11 July 2017]
   Google Scholar
• Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast Cancer. J Clin Oncol 2002;20:727-31
   PubMed Web of Science ®Google Scholar
• Green MD, Koebl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35
   PubMed Web of Science ®Google Scholar
• Siena S, Piccart MJ, Holmes FA, et al. A combined analysis of two pivotal randomized trials of single dose pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer. Oncol Rep 2003;19:715-24
   Google Scholar
• Pinto L, Liu Z, Doan Q, et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2007;2283-95
   PubMed Web of Science ®Google Scholar
• Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011;11:404
   PubMed Web of Science ®Google Scholar
• Wang L, Baser O, Kutikova L, et al. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Canc 2015;23:3131-40
   PubMed Web of Science ®Google Scholar
• Klastersky J, Awada A. Prevention of febrile neutropenia in chemotherapy-treated cancer patients: pegylated versus standard myeloid colony stimulating factors. Do we have a choice? Crit Rev Oncol Hematol 2011;78:17-23
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Kümmel S, du Bois A, et al. Pegfilgrastim ± ciproflaxin for primary prophylaxis with TAX (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPATRIO study. Ann Oncol 2008;19:292-8
   PubMed Web of Science ®Google Scholar
• Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract 2012;18:171-9
   PubMedGoogle Scholar
• Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001;19:609-21
   PubMed Web of Science ®Google Scholar
• Lyman GH, Lalla A, Barron RL, et al. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther 2009;31:1092-104
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services. Medicare Part B Drug Average Sales Price. 2017 ASP Drug Pricing Files: January 2017 ASP Pricing File. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2017ASPFiles.html. [Last accessed 11 July 2017]
   Google Scholar
• Centers for Medicare and Medicaid Services, Medicare Learning Network. January 2017 Update of the Ambulatory Surgical Center (ASC) Payment System; 2016, MM9923. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM9923.pdf. [Last accessed 11 July 2017]
   Google Scholar
• AnalySource Online® (Selected from FDB MedKnowledge data included with permission and copyrighted by First Databank, Inc.). https://classic.analysource.com. [Last accessed 11 July 2017]
   Google Scholar
• Centers for Medicare and Medicaid Services. 2016 Medicare Physician Fee Schedule. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-Federal-Regulation-Notices-Items/CMS-1654-F.html. [Last accessed 11 July 2017]
   Google Scholar
• Weycker D, Hackett J, Edelsberg J, et al. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 2006;40:402-7
   PubMed Web of Science ®Google Scholar
• Gascón P, Aapro M, Ludwig H, et al. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). Support Care Canc 2016;24:911-25
   PubMed Web of Science ®Google Scholar
• QuintilesIMS. Biosimilars in Europe. http://www.quintiles.com/microsites/biosimilars-knowledge-connect/biosimilars-by-region/europe. [Last accessed 26 March 2017]
   Google Scholar
• EuropaBio Guide on Biosimilars in Europe; September 2014. http://www.europabio.org/healthcare-biotech/publications/guide-biosimilars-europe. [Last accessed 11 July 2017]
   Google Scholar
• IMS Health Thought Leadership, November 2013. The global use of medicines: outlook through 2017. Report by the IMS Institute for Healthcare Informatics. http://www.imshealth.com/en/thought-leadership/quintilesims-institute/reports/global-use-of-medicines-outlook-through-2017. [Last accessed 11 July 2017]
   Google Scholar
• GaBI Online; August 8, 2014. Use of biosimilars in Europe differs across countries. http://www.gabionline.net/Reports/Use-of-biosimilars-in-Europe-differs-across-countries. [Last accessed 11 July 2017]
   Google Scholar
• Generic Pharmaceutical Association. Generic drug savings in the US: Seventh Annual Edition; 2015. http://www.gphaonline.org/media/wysiwyg/PDF/GPhA_Savings_Report_2015.pdf. [Last accessed 11 July 2017]
   Google Scholar
• Kline RM, Bazell C, Smith E, et al. Centers for Medicare and Medicaid Services: using an episode-based payment model to improve oncology care. J Oncol Pract 2015;11:114-16
   PubMed Web of Science ®Google Scholar
• Abraham I, McBride A, MacDonald K. Arguing (about) the value of cancer care. J Natl Compr Canc Netw 2016;14:1487-9
   PubMed Web of Science ®Google Scholar
• Sun D, Andayani TM, Altyar A, et al. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study. Clin Ther 2015;37:842-57
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Gascón P, Aapro M, et al. Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study. Support Care Canc 2017;25:1819-28
   PubMed Web of Science ®Google Scholar
• Aapro M, Ludwig H, Bokemeyer C, et al. Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study). Ann Oncol 2016;27:2039-45
   PubMed Web of Science ®Google Scholar
• Gascón P, Fuhr U, Sörgel F, et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol 2010;21:1419-29
   PubMed Web of Science ®Google Scholar
• Tharmarajah S, Mohamed A, Bagalagel A, et al. Clinical efficacy and safety of Zarzio® (EP2006), a biosimilar recombinant human granulocyte colony-stimulating factor. Biosimilars 2014;4:1-9
   Google Scholar
• Abraham I, Tharmarajah S, MacDonald K. Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. Expert Opin Drug Saf 2013;12:235-46
   PubMed Web of Science ®Google Scholar